Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non–small-cell lung cancer
T Takano, Y Ohe, H Sakamoto, K Tsuta… - Journal of clinical …, 2005 - ascopubs.org
Purpose To evaluate epidermal growth factor receptor (EGFR) mutations and copy number
as predictors of clinical outcome in patients with non–small-cell lung cancer (NSCLC) …
as predictors of clinical outcome in patients with non–small-cell lung cancer (NSCLC) …
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non–small-cell lung cancer with …
T Mitsudomi, T Kosaka, H Endoh, Y Horio… - Journal of Clinical …, 2005 - ascopubs.org
Purpose To evaluate the relationship between mutations of the epidermal growth factor
receptor (EGFR) gene and the effectiveness of gefitinib treatment in patients with recurrent …
receptor (EGFR) gene and the effectiveness of gefitinib treatment in patients with recurrent …
Predictive and prognostic impact of epidermal growth factor receptor mutation in non–small-cell lung cancer patients treated with gefitinib
Purpose This study was undertaken to investigate the effects of epidermal growth factor
receptor (EGFR) mutation and its downstream signaling on response and survival in non …
receptor (EGFR) mutation and its downstream signaling on response and survival in non …
[HTML][HTML] Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer
Introduction: We evaluated the efficacy of gefitinib monotherapy prospectively in patients
with advanced or pretreated non-small cell lung cancer (NSCLC) harboring epidermal …
with advanced or pretreated non-small cell lung cancer (NSCLC) harboring epidermal …
Relative Abundance of EGFR Mutations Predicts Benefit From Gefitinib Treatment for Advanced Non–Small-Cell Lung Cancer
Q Zhou, XC Zhang, ZH Chen, XL Yin… - Journal of clinical …, 2011 - ascopubs.org
Purpose Our aim was to determine whether abundance of epidermal growth factor receptor
(EGFR) mutations in tumors predicts benefit from treatment with EGFR–tyrosine kinase …
(EGFR) mutations in tumors predicts benefit from treatment with EGFR–tyrosine kinase …
Optimization of patient selection for gefitinib in non–small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt …
Purpose: Mutations in epidermal growth factor receptor (EGFR) are strongly predictive of
gefitinib efficacy in non–small-cell lung cancer. However, the presence of EGFR mutant …
gefitinib efficacy in non–small-cell lung cancer. However, the presence of EGFR mutant …
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non–small-cell lung cancer
FR Hirsch, M Varella-Garcia, PA Bunn Jr… - Journal of clinical …, 2006 - ascopubs.org
Purpose The phase III Iressa Survival Evaluation in Lung Cancer (ISEL) trial compared
gefitinib with placebo in 1,692 patients with refractory advanced non–small-cell lung cancer …
gefitinib with placebo in 1,692 patients with refractory advanced non–small-cell lung cancer …
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non–small cell lung cancer patients treated with gefitinib or …
DM Jackman, BY Yeap, LV Sequist, N Lindeman… - Clinical Cancer …, 2006 - AACR
Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …
First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations
LV Sequist, RG Martins, D Spigel… - Journal of clinical …, 2008 - ascopubs.org
Purpose Somatic mutations in the epidermal growth factor receptor (EGFR) correlate with
increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR …
increased response in patients with non–small-cell lung cancer (NSCLC) treated with EGFR …
Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
JY Wu, SG Wu, CH Yang, CH Gow, YL Chang… - Clinical Cancer …, 2008 - AACR
Purpose: Clinical reports about responsiveness to gefitinib treatment in patients of non-small
cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor …
cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor …